Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2025)

Xeris Biopharma Holdings' Change in Accured Expenses history spans 6 years, with the latest figure at $2.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 45.1% year-over-year to $2.3 million, compared with a TTM value of $3.7 million through Dec 2025, up 2.0%, and an annual FY2025 reading of $3.7 million, up 2.0% over the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.3 million at Xeris Biopharma Holdings, up from $297000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $14.6 million in Q4 2022, with the low at -$13.7 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $1.3 million, with a median of $1.8 million recorded in 2023.
  • Year-over-year, Change in Accured Expenses plummeted 1234.34% in 2024 and then surged 518.02% in 2025.
  • Tracing XERS's Change in Accured Expenses over 5 years: stood at $7.9 million in 2021, then soared by 85.2% to $14.6 million in 2022, then crashed by 86.67% to $2.0 million in 2023, then surged by 117.88% to $4.3 million in 2024, then tumbled by 45.1% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Change in Accured Expenses are $2.3 million (Q4 2025), $297000.0 (Q3 2025), and $9.7 million (Q2 2025).